A phase 3 trial compares ponatinib plus blinatumomab with imatinib plus chemotherapy as first-line treatment for adults with Philadelphia-positive acute lymphoblastic leukemia. Ponatinib Plus Blinatumomab Boosts EFS in Ph-Positive ALL A chemotherapy-free regimen combining ponatinib plus blinatumomab improved event-free survival (EFS)…
Experts at the 2025 ICE-T Symposium reviewed CAR T-cell therapy, bispecific antibodies, and gene therapy across myeloma, lymphoma, autoimmune disease, and solid tumors, emphasizing safety and access. The analysis included 128 patients treated with BCMA-directed CAR T-cell therapy between December 2019 and December…
(CTCL) is a disease that begins in T cells — a type of white blood cell that normally helps your immune system fight off infection. In CTCL, abnormal T cells travel to the skin, causing red, scaly patches, plaques or raised…
Cutaneous lymphoma is a group of non‑Hodgkin lymphomas (NHLs) that begin in the skin rather than in lymph nodes or internal organs. These cancers arise from lymphocytes (a type of white blood cell) and are broadly divided into cutaneous…
A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell leukemia, aiming for undetectable disease. Francesco Forconi: I am a Professor of Hematology at the University of Southampton, practicing at Southampton General Hospital. I…
A phase 2 trial evaluates the safety and efficacy of loncastuximab tesirine plus rituximab among older, unfit or frail patients with previously untreated diffuse large B-cell lymphoma. Loncastuximab Plus Rituximab Raises Safety Concerns Despite Responses in Frail Patients With Untreated DLBCL…
UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers. The Institute for Value-Based Medicine®, hosted by The American Journal of Managed Care® (AJMC®), held its October 1, 2026, meeting in Birmingham,…
Anaplastic large cell lymphoma is a rare type of non-Hodgkin lymphoma that primarily affects T cells. While most cases respond well to conventional chemotherapy, achieving long-term survival rates as high as in 80-90%, a subset of patients require more extensive treatment.
As a first treatment for someone with a rare white blood cell cancer (MTCL), giving someone stem cells from another person (alloSCT) rather than their own stem cells (autoSCT) may make little or no difference to their chance of treatment…
Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma. In an interview with CancerNetwork® at the 2026... In an interview with CancerNetwork® at the 2026 Society of Hematologic Oncology (SOHO)…
Hodgkin and non-Hodgkin lymphoma, from follicular to large B-cell: treatment, CAR-T and bispecific antibodies, and research.
An article joins this feed when it matches these terms. Each one is also a search of its own.